PharVision Advisers’s ESAB ESAB Stock Holding History

PharVision Advisers’s Portfolio ESAB Stock Details ESAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,075	Closed	-$232K	–	274
2025 Q4	$232K	Buy	+2,075	New	+$237K	0.12%	438

Other funds holding ESAB

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return

PharVision Advisers's ESAB Position: Q1 2026 in Review

PharVision Advisers sold out of ESAB (ESAB) in Q1 2026, closing a stake of 2,075 shares — an estimated $232K sold.

PharVision Advisers first reported a position in ESAB in Q4 2025 and held it in 1 quarter. The position peaked at $232K in Q4 2025. 350 funds tracked by Wall St. Rank hold ESAB as of Q1 2026.

PharVision Advisers reported no remaining ESAB position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 2,075 ESAB shares in Q1 2026, an estimated $232K.
PharVision Advisers first reported a position in ESAB in Q4 2025 and held it in 1 quarter.
PharVision Advisers's ESAB position peaked at $232K in Q4 2025.
350 funds tracked by Wall St. Rank held ESAB as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.